There is provided a method by which microtags can be attached to a product at a product processing facility other than the manufacturer such as a dispensing pharmacy. Also, it is an object to attach microtags to a hard capsule in a simple manner. There is provided a band seal preparation liquid for sealing a hard capsule, the band seal preparation liquid containing microtags that enable a product to be identified.

An aqueous composition for making dip-molded comestible hard capsules comprising a film forming capsule base material and one or more colorants each consisting of a hydrophilic coloring foodstuff concentrate.

A pullulan empty hard capsule and a preparation method therefor. The empty hard capsule includes the following components: 82-89 wt % of pullulan having a pH of 6-7, 1-1.4 wt % of gelling agent, 0.8-1.4 wt % of coagulant aid, 0.01-0.04 wt % of humectant, 0.01-0.04 wt % of surfactant, and 10-14 wt % of purified water. The preparation method for the pullulan empty hard capsule includes: weighing the components; dissolving the gelling agent, the coagulant aid, the humectant, the surfactant, a light-screening agent, a food coloring with 80-90° C. purified water, putting the dissolved substances into a gel dissolving barrel, stirring till the gelling agent is dissolved, adding the pullulan having a pH of 6-7 while stirring, after the pullulan is completely dissolved, cooling, preparing a capsule by means of a glue dipping method, and drying.

The present invention relates to a banding solution for manufacturing enteric hard capsules and an enteric hard capsule manufactured using the same, and specifically, relates to banding solution for manufacturing enteric hard capsules, which prevent the generation of a gap between the coupled capsule upper portion and capsule lower portion due to gastric acid or the separation of the capsule upper portion and the capsule lower portion during the time the enteric hard capsules stay in the stomach, and an enteric hard capsule subjected to banding treatment using the same.

A pharmaceutical dosage form, comprising: a pharmaceutical unit which includes a drug, at least one unfolding member, and a retaining member, wherein the unfolding member is connected to the pharmaceutical unit, and is constructed to have a contracted shape, which makes the unfolding member become closer the pharmaceutical unit, and an unfolding shape, which makes the unfolding member become farther away from the pharmaceutical unit; the retaining member is connected to the at least one unfolding member, and applies a constraint force to the at least one unfolding member, so as to make the unfolding member be in the contracted shape; and the retaining member contains a water-soluble material, and is constructed to remove the constraint force from the unfolding member when the water-soluble material is dissolved, such that the at least one unfolding member can change from the contracted shape to the unfolding shape.

The present invention discloses a lubricating unit/apparatus/system and to the method of lubricating encapsulated soft gelatine capsules and, more particularly, to soft gelatin and non-gelatin capsules to overcome the problem of clumping and nesting of the soft gelatin capsules.

[Problem] Providing a whitened capsule and a whitened film without using any white pigment such as titanium dioxide.

[Solution] Provided is a film, a capsule, and a film forming composition, characterized by comprising: a film-forming polymer; and a whitening agent including either a surfactant or both a surfactant and a salt, and characterized in that the surfactant is selected from a fatty acid ester of polyhydric alcohol, a polyethylene glycol, a polypropylene glycol, a polyalkylene oxide derivative, an alkyl sulfate ester salt, and a saponin.

To provide a hard capsule composed of a hard capsule film that can be molded by a cold gelation method and has enteric properties. The problem is solved by an enteric hard capsule comprising a film (a) containing a first component and a second component, or (b) containing a first component and a second component, and further containing at least one component selected from a third component and a fourth component, wherein the first component is methylcellulose and/or hydroxypropyl methylcellulose having a viscosity value of 6 mPa.Math.s or more, the second component is an enteric methacrylic acid copolymer, the third component is a water-insoluble alkyl (meth)acrylate ester copolymer and/or ethyl cellulose, and the fourth component is at least one selected from the group consisting of a plasticizer and a surfactant acceptable pharmaceutically or as a food additive, and wherein the first component is contained at a rate of 30 to 70% by mass and the second component is contained at a rate of 30 to 60% by mass with the sum of the rates of the first component and the second component being 70% by mass or more based on the total mass of the first component, the second component, the third component and the fourth component contained in the film, which is taken as 100% by mass.

Disclosed are novel pharmaceutical formulation containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid or a pharmaceutically acceptable salt thereof and processes for preparing the same.

The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.